Adrecizumab (HAM8101) to Improve Prognosis and Outcomes in COVID-19 Trial
Clinical trial NCT05156671 · TERMINATED
Trial details
- NCT number
- NCT05156671
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-06
- Primary completion
- 2023-08-25
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.